Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does METOCLOPRAMIDE Cause C-reactive protein increased? 25 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 25 reports of C-reactive protein increased have been filed in association with METOCLOPRAMIDE (metoclopramide hydrochloride). This represents 0.2% of all adverse event reports for METOCLOPRAMIDE.

25
Reports of C-reactive protein increased with METOCLOPRAMIDE
0.2%
of all METOCLOPRAMIDE reports
1
Deaths
10
Hospitalizations

How Dangerous Is C-reactive protein increased From METOCLOPRAMIDE?

Of the 25 reports, 1 (4.0%) resulted in death, 10 (40.0%) required hospitalization, and 8 (32.0%) were considered life-threatening.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for METOCLOPRAMIDE. However, 25 reports have been filed with the FAERS database.

What Other Side Effects Does METOCLOPRAMIDE Cause?

Nausea (1,080) Drug ineffective (927) Off label use (926) Drug hypersensitivity (751) Vomiting (672) Dyspnoea (525) Headache (499) Diarrhoea (481) Hypersensitivity (473) Tardive dyskinesia (465)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which METOCLOPRAMIDE Alternatives Have Lower C-reactive protein increased Risk?

METOCLOPRAMIDE vs METOLAZONE METOCLOPRAMIDE vs METOPIMAZINE METOCLOPRAMIDE vs METOPROLOL METOCLOPRAMIDE vs METRELEPTIN METOCLOPRAMIDE vs METRONIDAZOLE

Related Pages

METOCLOPRAMIDE Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased METOCLOPRAMIDE Demographics